RUNX1 and Miyoshi myopathy: Some of these represent well-studied lineage survival oncogenes, including RUNX1/MYB/IRF4/NFKB1/MEF2C (module #1) in LAML, ALL, MM and DLBC36,37, and MITF/SOX10 (module #20) in cutaneous melanoma38 (Supplementary Fig. 2b); whereas others are yet to be characterized, such as STXBP3/STX4/SNAP23 (module #15) in head and neck cancers (Supplementary Fig. 2b).